Diabetes reversal startup Breathe Well-being raises Rs 50Cr in funding led by 3One4 Capital, Accel, others

Diabetes Reversal startup Breathe Well-being has raised Rs 50 crore in a pre-Series B funding round co-led by 3One4 Capital, Accel and General Catalyst. The round also saw participation from FounderBank Capital and Supermorpheus.

The startup plans to use the funds to strengthen its coaching academy, expand the core team, and scale up the technology platform to enhance customer experience.

Breathe Well-being said it offers a simple and effective alternative to medicines to prevent, manage and reverse Type 2 Diabetes.

The Gurgaon-based health-tech startup was founded by Rohan Verma (ex-McKinsey) & Aditya Kaicker (ex-Accenture) in 2020, who come with a deep understanding of healthcare, wellness and life sciences domain.

The team strongly believes that medication is not a long-term solution for diabetes and instead focuses on behavioural & lifestyle changes for Diabetes reversal and reducing the risk of chronic lifestyle diseases.

Rohan Verma, Co-founder & CEO of Breathe Well-being, said, “India is the diabetes capital of the world and we are on a mission to change that. Our aim is a Diabetes Mukt Bharat (Diabetes Free India) with the aim to reverse diabetes for 1 Million Indians by 2025 and we are well on track to achieve that goal. Referral is our strongest growth lever especially in non-metros and more than half our customers come through word of mouth.”

Radhika Ananth, Vice President of Accel, “We have been impressed by how quickly Breathe Well-being is becoming a household name for Type 2 Diabetes & Pre-Diabetes Reversal across Tier 2 and 3 cities of India. I realised the true value of what Rohan and Aditya are building at Breathe Well-being after seeing my own mother go through the program and reduce her HbA1c levels significantly. Hence Accel invested and we continue to back them in their vision of building a Diabetes Mukt Bharat.”

The startup claims that its Diabetes Reversal Program helps reduce HbA1c levels, lose weight, improve glucose tolerance and stop diabetes medication eventually.

Breathe said it is the only digital health tech company across Asia to have published clinical evidence in 3 journals; the American Diabetes Association, the European Society of Endocrinology, and the American Association of Clinical Endocrinology.

With strong conviction in its program and its medical care team, Breathe is taking its promise of a diabetes-free life a notch higher with its “No Outcome, No Pay” policy - Diabetic patients pay only if they see a significant reduction in the HbA1c levels or medication reduction else the fees are refunded.

Breathe Well-being’s current core team comprises people from IITs, BITS Pilani, and top tier consulting firms like McKinsey, and Accenture and is rapidly expanding across Product, Growth, Technology & Analytics.

Breathe added that it wants to extend its digital therapeutic offerings to other chronic conditions, such as hypertension, PCOS, gut disorders, etc., and establish itself as a leading health & wellness player globally.

Also Read:

• IPO-bound PhonePe raises $350M at a valuation of $12B

Follow IndianStartupNews on Facebook, Instagram, Twitter for the latest updates from the startup ecosystem.